Abstract: The present invention relates to nucleic acid sequences encoding novel Babesia canis associated proteins and to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences. Furthermore, the invention relates to host cells comprising such nucleic acid sequences, cDNA fragments, recombinant DNA molecules and live recombinant carriers. Also, the invention relates to proteins encoded by these nucleotide sequences, to vaccines for combating Babesia canis infections comprising these proteins or genetic material encoding these proteins and methods for the preparation of vaccines. Another embodiment of the invention relates to these Babesia canis associated proteins for use in vaccines and to the use of the Babesia canis associated proteins in the manufacture of vaccines.
Type:
Grant
Filed:
February 28, 2002
Date of Patent:
August 15, 2006
Assignee:
Akzo Nobel N.V.
Inventors:
Theodorus Petrus Maria Schetters, Bernard Pierre Dominique Carcy, Pascal Robert Drakulovski
Abstract: Synthetic gene sequences encoding erythrocyte binding protein of a malaria pathogen for the expression of the erythrocyte binding protein. The codon composition of the synthetic gene sequences approximates the mammalian codon composition. The synthetic gene sequences are useful for incorporation into the DNA vaccine vectors, for the incorporation into various expression vectors for production of malaria proteins, or both. The synthetic genes may be modified to avoid post-translational modification of the encoded protein in hosts. Administration of the synthetic gene sequences, or the encoded protein, as an immunization agent is useful for induction of immunity against malaria, treatment of malaria, or both.
Type:
Grant
Filed:
November 12, 2002
Date of Patent:
July 18, 2006
Assignee:
The United States of America as represented by the Secretary, Department of Health and Human Services
Inventors:
David Narum, Hong Liang, Steve Fuhrmann, B. Kim Lee Sim
Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
Type:
Grant
Filed:
March 25, 2002
Date of Patent:
June 13, 2006
Assignee:
The United States of America as represented by the Secretary of the Army
Inventors:
David E. Lanar, Sheetij Dutta, Lisa A. Ware, Lalitha P. V. Nair
Abstract: The invention provides FabK polypeptides and polynucleotides encoding FabK polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing FabK polypeptides to screen for antibacterial compounds.
Type:
Grant
Filed:
November 26, 2002
Date of Patent:
June 6, 2006
Assignee:
Affinium Pharmaceuticals, Inc.
Inventors:
Walter E. DeWolf, Jr., David John Payne, Nicola Gail Wallis, Joshua M. West
Abstract: The invention provides antibodies reactive with distinct lipocalin epitopes that are useful for detecting inflammation and bacterial infections in mammals.
Abstract: Antibodies, polypeptides, and polynucleotides are provided for the detection, prevention, amelioration and treatment of diseases caused by Actinobacillus actinomycetemcomitans.
Type:
Grant
Filed:
November 28, 2001
Date of Patent:
May 30, 2006
Assignee:
University of Florida Research Foundation
Inventors:
Martin Handfield, Jeffrey Daniel Hillman, Ann Progulske-Fox
Abstract: The invention provides FabK polypeptides and polynucleotides encoding FabK polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are preferred methods for utilizing FabK polypeptides and polynucleotides as diagnostic reagents and in diagnostic assays to screen for microbial infections in organisms and infestations in materials.
Type:
Grant
Filed:
November 26, 2002
Date of Patent:
April 25, 2006
Assignee:
Affinium Pharmaceuticals, Inc.
Inventors:
Walter E. DeWolf, Jr., David John Payne, Nicola Gail Wallis, Joshua M. West
Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a protein for use alone, or as part of, a vaccine to prevent malaria.
Type:
Grant
Filed:
October 15, 2002
Date of Patent:
April 18, 2006
Assignee:
The United States of America as represented by the Secretary of the Army
Inventors:
David E. Lanar, Sheetij Dutta, Lisa A. Ware, Lalitha P. V. Nair
Abstract: The invention provides a novel process of lignin degradation using a consortium of bacteria. To date, biodegradation of lignin has been centered to fungi only. Degradation of lignin by bacteria confer a new understanding that may be of tremendous industrial significance. This invention also discloses the isolation and acclimatization of ligninolytic bacteria from a specific site.
Type:
Grant
Filed:
March 21, 2003
Date of Patent:
April 4, 2006
Assignee:
Council of Scientific & Industrial Research
Abstract: The present invention relates to antigens of Moraxella, in particular, Moraxella bovis, nucleic acid sequences encoding these antigens and formulations for use in raising an immune response against Moraxella.
Type:
Grant
Filed:
August 31, 2000
Date of Patent:
March 28, 2006
Assignees:
Commonwealth Scientific and Industrial Research Organisation, The University of Melbourne
Inventors:
Jacinta Farn, Richard Strugnell, Jan Tennent
Abstract: Methods for the diagnosis of visceral, cutaneous and canine leishmaniasis in a subject suspected of being infected with the parasitic protozoa Leishmania is disclosed. Disclosed are antibody-capture enzyme-linked immunosorbent assays (ELISAs) for the detection of antibodies to Leishmania parasite soluble antigens and antigen-capture ELISAs for the detection of Leishmania parasite soluble antigens in host samples. Also disclosed are immunodiagnostic kits for the detection of Leishmania parasite circulating antigens or IgM and IgG antibodies in a sample from subject having visceral, cutaneous or canine leishmaniasis. In these methods and kits, detection may be done photometrically or visually. The methods and kits also allow the visualization of Leishmania amastigotes or promastigotes in a sample.
Type:
Grant
Filed:
June 18, 2002
Date of Patent:
March 7, 2006
Assignee:
The United States of America as represented by the Secretary of the Army
Inventors:
Jeffrey R. Ryan, Samuel K. Martin, Anthony M. Smithyman
Abstract: This invention relates to polynucleotides, polypeptides encoded by these polynucleotides, to the production of such polynucleotides and polypeptides, and to the uses of such polynucleotides and polypeptides. More specifically, the invention relates to the phosphomevalonate kinase (PMK) gene (ERG8 gene) from Candida Albicans (C. albicans), to methods for its expression yielding phosphomevalonate kinase protein, to hybrid organisms for use in such expression methods, to methods for purification of the protein, to methods and tools for diagnosing C. albicans infection and to assays for identifying inhibitors of the enzyme which inhibitors have potential as anti-fungal agents.
Type:
Grant
Filed:
August 15, 2000
Date of Patent:
February 21, 2006
Assignee:
AstraZeneca AB
Inventors:
John David Charles Rosamund, Norbert Friedemann Schnell
Abstract: The invention provides Neisseria meningitidis BASB030 polypeptides and polynucleotides encoding BASB030 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are antibodies, diagnostic, prophylactic and therapeutic uses thereof.
Type:
Grant
Filed:
May 26, 1999
Date of Patent:
February 7, 2006
Assignee:
Smithkline Beecham Biologicals S.A.
Inventors:
Jean-Louis Ruelle, Johannes Petrus Maria Tommassen
Abstract: The invention relates to agents and processes for detecting bacteria of the genus Listeria, in particular L. monocytogenes. The agents according to the invention include primers whose sequence is selected from the iap gene of L. monocytogenes. In addition, the agents according to the invention include peptides whose sequence is selected from the p60 protein and which are suitable for producing specific antibodies for the immunological detection of L. monocytogenes.
Type:
Grant
Filed:
August 11, 1999
Date of Patent:
October 4, 2005
Assignee:
Merck Patent Gesellschaft mit beschrankter
Inventors:
Peter Schubert, Siegfried Neumann, Martina Pawelzik, Winfried Linxweiler, Christa Burger, Andreas Bubert, Werner Goebel, Stefan Köhler
Abstract: A series of genes from Streptococcus pyogenes are shown to encode products which are implicated in virulence. The identification of these genes therefore allows attenuated microorganisms to be produced. Furthermore, the genes or their encoded products can be used in the manufacture of vaccines for therapeutic application.
Type:
Grant
Filed:
December 22, 2000
Date of Patent:
October 4, 2005
Assignee:
VMAX Ltd.
Inventors:
Enda Elizabeth Clarke, Liqing Zhou, Jacqueline Elizabeth Shea, Robert Graham Feldman, David William Holden
Abstract: Lethal Toxin Neutralizing Factor has been isolated in purity from opossum serum by high pressure liquid chromatography (HPLC) fractionation. The amino acid sequence from the N-terminal for the first fifteen amino acids of LTNF-n is: Leu Lys Ala Met Asp Pro Thr Pro Pro Leu Trp Ile Lys Thr Glu. Antibodies to LTNF-n and synthetic peptides consisting of fifteen, ten and five amino acids from the N-terminal of the above sequence, designated as LTNF-15, LTNF-10 and LTNF-5 were produced by immunizing Balb/C mice to produce Anti-LTNF-n, Anti-LTNF-15, Anti-LTNF-10 and Anti-LTNF-5. The anti LTNF-n, anti-LTNF-15, anti-LTNF-10 and anti-LTNF-5 react immunologically with all types of toxins derived from animal, plant and bacteria and can be assayed by immunological in vitro test such as ELISA tests. Anti-LTNFs react roughly proportional to lethal dose of biological toxins under in vitro immunological ELISA test similar to the mouse bioassay test.
Abstract: Novel protein antigens from Streptococcus pneumoniae are disclosed, together with nucliec acid sequences encoding them. Their use in vaccines and in screening methods is also described.
Type:
Grant
Filed:
January 26, 2001
Date of Patent:
August 30, 2005
Assignee:
Microbial Technics Limited
Inventors:
Christophe Francois Guy Gilbert, Philip Michael Hansbro
Abstract: The invention relates to a compound that competitively inhibits binding of CSP to S. mutans histidine kinase. The compound is preferably a peptide or an antibody. The compound is preferably a derivative of [SEQ ID NO:2], a fragment of [SEQ ID NO:2] or a derivative of a fragment of [SEQ ID NO:2].
Type:
Grant
Filed:
April 10, 2001
Date of Patent:
August 2, 2005
Inventors:
Dennis Cvitkovitch, Peter C. Y. Lau, Yung Hua Li
Abstract: Disclosed are peptide and DNA compositions surprisingly found to be effective in generating immune responses against the pathogenic fungi Coccidioides spp., the causative agents of coccidioidomycosis and Valley Fever. The invention thus provides peptides and DNA constructs, combinations and related biological compositions, and prophylactic and therapeutic methods of using such components to generate effective immune responses against Coccidioides spp., including C. immitis.
Type:
Grant
Filed:
February 22, 2002
Date of Patent:
August 2, 2005
Assignee:
Board of Regents, The University of Texas System
Inventors:
Rebecca A. Cox, D. Mitchell Magee, Chengyong Jiang